Q-omics provides the consensus-scored SEMA7A profile across patient tissues and cancer cell-line models. SEMA7A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SEMA7A is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, SEMA7A protein abundance shows 25,420 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, HNSC, and GBM as cancer lineages where SEMA7A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEMA7A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEMA7A survival associations across molecular data types. SEMA7A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEMA7A RNA expression–survival associations across cancer types. High SEMA7A expression shows unfavorable associations in KIRP, MESO, ACC, KIRC and UVM, but favorable associations in UCEC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SEMA7A RNA expression.
This table summarizes SEMA7A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SEMA7A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEMA7A shows lower tumor expression in KIRP and higher tumor expression in HNSC, LUAD, STAD, LIHC and BRCA. The HNSC box plot shows higher SEMA7A RNA expression in tumor versus normal tissue (log2 FC = +1.296, t-test p < 0.001).
This table shows molecular features associated with SEMA7A in patient tissues and cancer cell lines. In patient samples, SEMA7A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SEMA7A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
